How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Ophthalmology for Age-related Macular Degeneration Diseases Market
- By Disease Type: Dry AMD (Atrophic), Wet AMD (Neovascular or Exudative), Polypoidal Choroidal Vasculopathy (PCV)
- By Treatment Type: Anti-VEGF Therapy, Photodynamic Therapy (PDT), Laser Therapy, Nutritional Supplements, Radiation Therapy
- By Drug Class: Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Corticosteroids, Complement Inhibitors
- By End User: Hospitals, Specialty Eye Clinics, Ambulatory Surgical Centers, Research Institutes
- By Mode of Administration: Intravitreal Injection, Oral Medication, Topical Eye Drops
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Dry AMD (Atrophic) leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Ophthalmology for Age-related Macular Degeneration Diseases Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Disease Type 3
Treatment Type 5
Drug Class 4
End User 4
Mode of Administration 3
Companies profiled
Novartis AG
Regeneron Pharmaceuticals Inc.
Roche Holding AG
Bayer AG
Allergan (AbbVie Inc.)
Genentech (Roche subsidiary)
Santen Pharmaceutical Co. Ltd.
Ophthotech Corporation
Kodiak Sciences Inc.
Iveric Bio Inc.
Gyroscope Therapeutics Ltd.
Apellis Pharmaceuticals Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Regeneron Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Allergan (AbbVie Inc.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Genentech (Roche subsidiary)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Santen Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Ophthotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Kodiak Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Iveric Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Gyroscope Therapeutics Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Apellis Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Chiesi Farmaceutici S.p.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Alcon (Novartis subsidiary)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Helsinn Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,731M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Dry AMD (Atrophic)66.8
- Wet AMD (Neovascular or Exudative)23.0
- Polypoidal Choroidal Vasculopathy (PCV)10.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,240M → $2,096M · 6.8%
Europe$864.4M → $1,275M · 5.0%
Asia Pacific$789.2M → $1,182M · 5.2%
Latin America$488.6M → $797.5M · 6.3%
Middle East and Africa$375.8M → $535.6M · 4.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.372026
5.372027
5.392028
5.402029
5.422030
5.432031
5.442032
5.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG14.6
- Regeneron Pharmaceuticals Inc.18.1
- Roche Holding AG10.5
- Bayer AG8.5
- Allergan (AbbVie Inc.)9.3
- Genentech (Roche subsidiary)11.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type18.4%
Treatment Type11.1%
Drug Class27.1%
End User32.4%
Mode of Administration11.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe21.7
- Asia Pacific20.1
- Latin America13.5
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 91 | 78 | 81 | 94 | 82 | 97 | 87 |
| Regeneron Pharmaceuticals Inc. | 88 | 86 | 81 | 83 | 75 | 87 | 83 |
| Roche Holding AG | 82 | 70 | 83 | 83 | 79 | 78 | 79 |
| Bayer AG | 64 | 57 | 64 | 57 | 74 | 81 | 66 |
| Allergan (AbbVie Inc.) | 62 | 66 | 62 | 68 | 62 | 59 | 63 |
| Genentech (Roche subsidiary) | 47 | 64 | 59 | 50 | 70 | 55 | 58 |
| Santen Pharmaceutical Co. Ltd. | 49 | 43 | 43 | 58 | 57 | 66 | 53 |
| Ophthotech Corporation | 43 | 55 | 40 | 39 | 57 | 48 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Regeneron Pharmaceuticals Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Roche Holding AG | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Bayer AG | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Allergan (AbbVie Inc.) | ◐ | − | ✓ | ◐ | ◐ | − |
| Genentech (Roche subsidiary) | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Santen Pharmaceutical Co. Ltd. | − | − | − | − | − | ◐ |
| Ophthotech Corporation | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG87
2Regeneron Pharmaceuticals Inc.83
3Roche Holding AG79
4Bayer AG66
5Allergan (AbbVie Inc.)63
6Genentech (Roche subsidiary)58
7Santen Pharmaceutical Co. Ltd.53
8Ophthotech Corporation47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novartis AGRegeneron Pharmaceuticals Inc.Roche Holding AG
Contender3
Focused players with pockets of strength.
Bayer AGAllergan (AbbVie Inc.)Genentech (Roche subsidiary)
Niche2
Specialists in a single segment or region.
Santen Pharmaceutical Co. Ltd.Ophthotech Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Ophthalmology for Age-related Macular Degeneration Diseases Market — a $784M beachhead inside a $10.9B market.
Beachhead (SOM)$784Mobtainable near-term
Serviceable (SAM)$4.50Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Dry AMD (Atrophic)
Best fit — highest urgency & budget in Disease Type.
Economic buyer76 fit
Wet AMD (Neovascular or Exudative)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Polypoidal Choroidal Vasculopathy (PCV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Ophthalmology for Age-related Macular Degeneration Diseases Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation14%
Closed-won7%
$17.0KCAC
$79KLTV
4.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Ophthalmology for Age-related Macular Degeneration Diseases Market is a durable-growth opportunity — $4.15B by 2033, compounding at 7.9%.
TAM · 2025$2.26Btoday
TAM · 2033$4.15Bforecast
CAGR7.9%2027–2033
Cumulative$28.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.15BTotal addressable market
SAM$1.59BServiceable available market
SOM$287MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.15BLarge & growingTAM by 2033 at 7.9% CAGR
$1.59BServiceable nowreachable with today’s model
$287MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.24BBear5.1% CAGR
$4.15BBase7.9% CAGR
$5.31BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Ophthalmology for Age-related Macular Degeneration Diseases Market — a $5.34B market by 2033. Plan: grow share from 8.9% to 13.8%.
Market size · 2033$5.34Btotal addressable
Market CAGR11.5%2027–2033
Target share13.8%from 8.9% today
Revenue ambition$737Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 13.8% | On track |
| Revenue | $508M | $737M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 29.5% | 40.5% | Ahead |
| Customer retention | 89.4% | 96.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $93M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Ophthalmology for Age-related Macular Degeneration Diseases Market conversation — a $4.68B market you can size, segment and defend in minutes.
Market size · 2033$4.68Btotal opportunity
Growth7.8%CAGR to 2033
Addressable buyers1,506+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Novartis AGRegeneron Pharmaceuticals Inc.Roche Holding AGBayer AGAllergan (AbbVie Inc.)Genentech (Roche subsidiary)Santen Pharmaceutical Co. Ltd.Ophthotech Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Ophthalmology for Age-related Macular Degeneration Diseases Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Ophthalmology for Age-related Macular Degeneration Diseases Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Ophthalmology Excimer Laser Therapy Solutions Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportOphthalmology Equipment Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportOphthalmology Electronic Medical Records Software Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportOphthalmology Electronic Health Record Market
Market size, share, segmentation and regional forecast.
$323M market · 2025 base year
View reportOphthalmology EHR Software Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportOphthalmology Drugs & Devices Market
Market size, share, segmentation and regional forecast.
$894M market · 2025 base year
View reportOphthalmology Chart Monitor Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportOphthalmology Chart Display Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportOphthalmology Capsular Tension Ring Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportOphthalmology Camera Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportOphthalmology Biometer Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportOphthalmology AI-assisted Diagnosis Software Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.